# Deerfield Capital Management

> Deerfield Capital Management is a VC fund backing Health Care. See 53 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Rosamond, United States
- Total investments: 53
- Last investment: Jun 2023
- Lead investor: 28%
- Last updated: Aug 2026
- Website: http://www.deerfieldcapital.com

Deerfield Capital Management ("DCM") is a global fixed-income investment adviser that has managed institutional, alternative accounts since 1993.

## Contacts

5 contacts available for Deerfield Capital Management. Shizune tracks 13 team members at Deerfield Capital Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/deerfield-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 36 | 68% |
| Biotechnology | 35 | 66% |
| Medical | 18 | 34% |
| Pharmaceutical | 17 | 32% |
| Therapeutics | 12 | 23% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 9 | 17% |
| Series B | 7 | 13% |
| Series D | 6 | 11% |
| Post-IPO Equity | 6 | 11% |
| Series A | 5 | 9% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 41 | 77% |
| Israel | 2 | 4% |
| United Kingdom | 2 | 4% |
| Canada | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| James Flynn | Managing Partner & CEO | 22 | https://shizune.co/investors/profile/james-e-flynn |
| Jonathan Leff | Partner | 10 | https://shizune.co/investors/profile/jonathan-leff |
| Lawrence S. Atinsky | Partner | 0 | https://shizune.co/investors/profile/lawrence-s-atinsky |
| Steven Hochberg | Partner | 12 | https://shizune.co/investors/profile/steven-hochberg |
| William Slattery | Partner | 5 | https://shizune.co/investors/profile/william-slattery |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Adaptive Phage Therapeutics | Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistantbacteria. | $12M | Series B | Jun 09, 2023 |  |
| Epic Sciences | Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $24M | Series G | Apr 14, 2023 |  |
| Ascend Gene & Cell Therapies | Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form. | $65.9M | Series A | Mar 20, 2023 |  |
| ConcertoCare | ConcertoCare serves patients with Medicare+Medicaid, Medicare Advantage or Medicare, who have complex care needs and an existing primary care provider (PCP). Patients keep their existing doctors and benefit plans. | $105M | Series B | Feb 03, 2022 |  |
| Quartet Health | Quartet is a platform that makes it easier for people to get the best mental health care for them. The best care should fit their preferences and clinical needs, take their insurance, and link to the rest of their healthcare experience. | $7.5M | Series D | Dec 02, 2019 |  |
| GrayBug | GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and itsown therapeutic products for major ocular disease indications including wet AMD and Glaucoma.The company was founded in 2011 and headquartered in Baltimore, Maryland. |  | Series C | Aug 20, 2019 |  |
| Frequency Therapeutics | Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts. | $62M | Series C | Jul 23, 2019 |  |
| Revolution Medicines | Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois atUrbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology.REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates. | $100M | Series C | Jul 09, 2019 |  |
| Acutus Medical | Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California. | $70M | Debt Financing | Jun 20, 2019 |  |
| Acutus Medical | Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California. | $100M | Series D | Jun 20, 2019 |  |

10 of 53 investments shown.

## Co-investors
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 14 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 6 deals together
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 4 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 4 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 3 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Deerfield Capital Management invest in?

Deerfield Capital Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series B stage. Most of the 53 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Deerfield Capital Management?

Public channels for Deerfield Capital Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Deerfield Capital Management?

The team at Deerfield Capital Management includes James Flynn (Managing Partner & CEO), Jonathan Leff (Partner) and Lawrence S. Atinsky (Partner), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co